A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema
- AOPR Vol. 2, Issue 2, Pages: 100051(2022)
- 作者机构：
1. ,Hangzhou,China
2. ,Coventry,UK
- 作者简介：
- 基金信息：
DOI：10.1016/j.aopr.2022.100051
CLC：
扫 描 看 全 文
Zhiqing Chen, Binbin Chen, Peike Hu, et al. A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema. [J]. AOPR 2(2):100051(2022)
Zhiqing Chen, Binbin Chen, Peike Hu, et al. A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema. [J]. AOPR 2(2):100051(2022) DOI： 10.1016/j.aopr.2022.100051.
摘要
Purpose,To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME).,Methods,It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. ,P, ,<, 0.05 was considered statistically significant.,Results,No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (,P, ,<, 0.05). All follow-up results of foveal thickness were not significantly different (,P, ,>, 0.05) from the baseline result, except that in the 6th month (,P, = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images.,Conclusions,PBM is a safe and effective treatment of DME, which deserves further investigation.
Abstract
Purpose,To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME).,Methods,It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. ,P, ,<, 0.05 was considered statistically significant.,Results,No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (,P, ,<, 0.05). All follow-up results of foveal thickness were not significantly different (,P, ,>, 0.05) from the baseline result, except that in the 6th month (,P, = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images.,Conclusions,PBM is a safe and effective treatment of DME, which deserves further investigation.
关键词
Keywords
Dark adaptationDiabetic macular edemaDiabetic retinopathyPhotobiomodulationRod cells
references
1 D.S.W. Ting, G.C.M. Cheung, T.Y. WongDiabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review Clin Exp Ophthalmol, 44 (4) (2016), pp. 260-277, 10.1111/ceo.12696 [published Online First: Epub Date]
2 P. Mello Filho, G. Andrade, A. Maia, et al.Effectiveness and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: A real-world experience Ophthalmologica, 241 (1) (2019), pp. 9-16, 10.1159/000492132 [published Online First: Epub Date]|
3 M. Iglicki, C. Busch, D. Zur, et al.Dexamethasone implant for diabetic macular edema IN naive compared with refractory eyes: The international retina group real-life 24-month multicenter study. The IRGREL-DEX study Retina, 39 (1) (2019)
4 M. Iglicki, A. Loewenstein, A. Barak, et al.Outer retinal hyperreflective deposits (ORYD): a new OCT feature in naïve diabetic macular oedema after PPV with ILM peeling Br J Ophthalmol, 104 (5) (2020), p. 666, 10.1136/bjophthalmol-2019-314523 [published Online First: Epub Date]
5 D. Zur, M. Iglicki, A. LoewensteinThe role of steroids in the management of diabetic macular edema Ophthalmic Res, 62 (4) (2019), pp. 231-236, 10.1159/000499540 [published Online First: Epub Date]|
6 S. Gudla, D. Tenneti, M. Pande, et al.Diabetic retinopathy: pathogenesis, treatment, and complications J.K. Patel, V. Sutariya, J.R. Kanwar, Y.V. Pathak (Eds.), Drug Delivery for the Retina and Posterior Segment Disease, Springer International Publishing, Cham (2018), pp. 83-94
7 G.B. Arden, R.L. Sidman, W. Arap, et al.Spare the rod and spoil the eye Br J Ophthalmol, 89 (6) (2005), pp. 764-769, 10.1136/bjo.2004.062547 [published Online First: Epub Date]
8 S. Sivaprasad, G. ArdenSpare the rods and spoil the retina: revisited Eye, 30 (2) (2016), p. 189
9 J.C. Muste, M.W. Russell, R.P. SinghPhotobiomodulation therapy for age-related macular degeneration and diabetic retinopathy: a review Clin Ophthalmol, 15 (2021), pp. 3709-3720, 10.2147/OPTH.S272327 [published Online First: Epub Date]|
10 G. Arden, S. Jyothi, C. Hogg, et al.Regression of early diabetic macular oedema is associated with prevention of dark adaptation Eye, 25 (12) (2011), p. 1546
11 S. Sivaprasad, G. Arden, A.T. Prevost, et al.A multicentre phase III randomised controlled single-masked clinical trial evaluating the cl inical e fficacy and safety o f light-masks at p reventing dark-a daptation in the tr eatment of ea rly diabetic macular oedema (CLEOPATRA): study protocol for a randomised controlled trial Trials, 15 (1) (2014), p. 458, 10.1186/1745-6215-15-458 [published Online First: Epub Date]|
12 S. Sivaprasad, J.C. Vasconcelos, A.T. Prevost, et al.Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial Lancet Diabetes Endocrinol, 6 (5) (2018), pp. 382-391, 10.1016/S2213-8587(18)30036-6 [published Online First: Epub Date]|
13 P. Song, J. Yu, K.Y. Chan, et al.Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis J. Global Health, 8 (1) (2018)
14 Y. Xu, L. Wang, J. He, et al.Prevalence and control of diabetes in Chinese adults JAMA, 310 (9) (2013), pp. 948-959, 10.1001/jama.2013.168118%J JAMA[published Online First: Epub Date]|
15 G. ArdenThe absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment Br J Ophthalmol, 85 (3) (2001), pp. 366-370
16 G.B. Arden, M.K. Gündüz, A. Kurtenbach, et al.A preliminary trial to determine whether prevention of dark adaptation affects the course of early diabetic retinopathy Eye, 24 (7) (2010), pp. 1149-1155, 10.1038/eye.2009.328 [published Online First: Epub Date]|
17 J. Tang, Y. Du, C.A. Lee, et al.Low-intensity far-red light inhibits early lesions that contribute to diabetic retinopathy: in vivo and in VitroFar-red light inhibits DR Investig Ophthalmol Vis Sci, 54 (5) (2013), pp. 3681-3690, 10.1167/iovs.12-11018 [published Online First: Epub Date]|
18 W. Shen, K.Y.C. Teo, J.P.M. Wood, et al.Preclinical and clinical studies of photobiomodulation therapy for macular oedema Diabetologia, 63 (9) (2020), pp. 1900-1915, 10.1007/s00125-020-05189-2 [published Online First: Epub Date]|
19 Phototherapeutic contact lens for diabetic retinopathy 2018 IEEE Micro Electro Mechanical Systems (MEMS) (2018 21-25 Jan. 2018)
20 J.E. Kim, A.R. Glassman, K. Josic, et al.A randomized trial of photobiomodulation therapy for center-involved diabetic macular edema with good visual acuity (protocol AE) Ophthalmol Retina, 6 (4) (2022), pp. 298-307, 10.1016/j.oret.2021.10.003
21 G.-H. Lee, C. Jeon, J.W. Mok, et al.Smart wireless near-infrared light emitting contact lens for the treatment of diabetic retinopathy Adv Sci (2022), Article 2103254, 10.1002/advs.202103254 n/a(n/a) [published Online First: Epub Date]|
22 G. Merry, R. Dotson, R. Devenyi, et al.Photobiomodulation as a new treatment for dry age related macular degeneration. Results from the toronto and Oak ridge photobimodulation study in AMD (TORPA) Investig Ophthalmol Vis Sci, 53 (14) (2012) 2049-49
0
Views
0
下载量
0
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.